Drug intelligence / Profile preview

SG-239

Development stage: Preclinical
Lead developer: Sana Biotechnology
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

SG-239 is a preclinical gene therapy and T-lymphocyte cell therapy developed by Sana Biotechnology. It is designed as an engineered cell product involving the modulation of BCMA (B-cell maturation antigen) and CD8 (Cluster of differentiation 8), targeting cancer immunotherapy via T cell replacement, immunologic cytotoxicity, and modulation of immune cell activity. Its primary indication is multiple myeloma, but it is also being explored for other neoplasms, immune system diseases, and cardiovascular diseases.

Targets

BCMA (B-cell maturation antigen)CD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on SG-239.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SG-239.

Explore the full profile